Moderna uncloaks 'profound' immune-evading mRNA therapeutic platform

Moderna Therapeutics has raised an impressive $40 million-plus in its first 18 months to fund technology that represents a profound change from established biological manufacturing - messenger RNA (mRNA) injected into the body and taken up by cells whose ribosomes then use the mRNA to produce therapeutic intra-cellular or secreted proteins.

Moderna Therapeutics has raised an impressive $40 million-plus in its first 18 months to fund technology that represents a profound change from established biological manufacturing - messenger RNA (mRNA) injected into the body and taken up by cells whose ribosomes then use the mRNA to produce therapeutic intra-cellular or secreted proteins.

In fact, Moderna president and CEO Stéphane Bancel told Scrip that the Cambridge, Massachusetts-based company's platform represents such a shift...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category